6-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-9,11-dihydro-6H-indeno[4,5-h]isochromene-1,4,7-trione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-9,11-dihydro-6H-indeno[4,5-h]isochromene-1,4,7-trione
• 化学式: C₂₀H₂₀O₆
• 分子量: 356.4
• InChiKey: VWHBVURQVLCWEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP2958943A1

  公开（公告）日：2015-12-30
• ANTIBODY DRUG CONJUGATES
  申请人：Petropoulos, Konstantin

  公开号：EP2968600A2

  公开（公告）日：2016-01-20
• [EN] TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR<br/>[FR] TRAITEMENT DU CANCER AU MOYEN D'UN RÉCEPTEUR D'ANTIGÈNES CHIMÉRIQUES ANTI-EGFRVIII HUMANISÉS
  申请人：UNIV PENNSYLVANIA

  公开号：WO2014130657A1

  公开（公告）日：2014-08-28

  The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti- EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
• [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-ANTICORPS
  申请人：BATT DAVID BRYANT

  公开号：WO2014163714A2

  公开（公告）日：2014-10-09

  The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.